Board meeting on 20 October 2026 to consider half-year results; trading window closed
Board meeting set for Tuesday, 20 October 2026.
By ScoutQuest · · 1 min read
- Board Meeting Date
- Tuesday, 20 October 2026
- Agenda
- unaudited financial results for the half year ended 30 September 2026, plus the limited review report
- Trading Window Closed
- from 1 October 2026 till 48 hours after the results are declared
The company has notified the exchange about the next meeting of its Board of Directors.
What the meeting is for
- The Board will meet on Tuesday, 20 October 2026.
- It will consider and approve the unaudited financial results for the half year ended 30 September 2026.
- It will also take on record the limited review report on those results.
What a limited review report means
A limited review is a check by the company's auditors on the half-yearly numbers. It is lighter than a full audit, but it gives investors the comfort that the figures have been looked at by an independent auditor. A limited review report will accompany the results once they are approved.
Trading window
- The trading window for dealing in the company's securities has been closed from 1 October 2026.
- It will remain closed until completion of 48 hours after the declaration of the financial results.
A trading window closure is a standard internal rule under the company's code of conduct for prohibition of insider trading. It is aimed at persons covered by that code so that they do not deal in the company's shares while they may be in possession of unpublished price-sensitive information till the results are out.
What to watch for
- The actual half-yearly numbers, which will come when the Board approves them.
- The limited review report that will be taken on record along with them.
What this update does not do
It does not give any numbers or any indication of how the half-year has performed. It is purely an intimation of the date of the meeting and the closure of the trading window. Nothing about the company's earnings, revenue or profit can be read from this notice.
Also from Aptus Pharma
Aptus Pharma reports H1 2026-27 revenue of ₹48.92 crore, targets own manufacturing, exports and Pan-India reach by 2029
23 Oct 2026
Aptus Pharma to host Q2 FY27 earnings conference call on October 26, 2026 at 5:00 PM IST
21 Oct 2026
Board approved unaudited H1 results; auditors' limited review finds no material misstatement
20 Oct 2026
More numbers
- Trading window closure period after declaration of results48 hours
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.